Compare · MTCR vs SISI
MTCR vs SISI
Side-by-side comparison of Metacrine Inc. (MTCR) and Shineco Inc. (SISI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MTCR and SISI operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- MTCR has more recent analyst coverage (4 ratings vs 0 for SISI).
- Company
- Metacrine Inc.
- Shineco Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- +0.00%
- 1Y return
- -
- +0.00%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2016
- News (4w)
- 0
- 0
- Recent ratings
- 4
- 0
Metacrine Inc.
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis patients. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Shineco Inc.
Shineco, Inc., together with its subsidiaries, produces, distributes, and sells health and well-being focused plant-based products in China. It processes and distributes traditional Chinese herbal medicine products, as well as other pharmaceutical products directly to individual customers. The company also plants, processes, and distributes green and organic vegetables and fruits; and grows, cultivates, and sells yew trees that are used for the production of anti-cancer medication, as well as ornamental bonsai trees for purifying indoor air quality. In addition, it offers logistics services for agricultural products. Further, the company develops, manufactures, and distributes specialized fabrics, textiles, health supplements, and other byproducts derived from an indigenous Chinese plant Apocynum Venetum. The company sells its Chinese medicinal products and western medicines through wholesale customers; and its 13 Ankang retail pharmacies operating under the Sunsimiao Pharmacies name, as well as 66 pharmacies operated by third parties. It sells its decoction pieces on the Anhui Bozhou Chinese medicine transaction market to medical materials companies and Chinese patent medicine factories. The company sells its Luobuma textile products online through third party e-commerce websites, as well as through distributors under the Tenethealth brand; and yew trees and agricultural products primarily through its sales personnel, and group and institutional sales. The company was formerly known as Beijing Tenet Jove Technological Development Co., Ltd. and changed its name to Shineco, Inc. in June 2005. Shineco, Inc. was incorporated in 1997 and is based in Beijing, China.
Latest MTCR
- SEC Form 15-12G filed by Metacrine Inc.
- Metacrine Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Leadership Update, Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Klassen Preston
- SEC Form S-8 POS filed by Metacrine Inc.
- SEC Form S-8 POS filed by Metacrine Inc.
- Metacrine Inc. filed SEC Form 8-K: Leadership Update
- Metacrine Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets
- SEC Form EFFECT filed by Metacrine Inc.
- SEC Form 25-NSE filed by Metacrine Inc.
- SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)
Latest SISI
- Shineco Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events
- SEC Form NT 10-K filed by Shineco Inc.
- Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines
- Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries
- Shineco (NASDAQ: SISI) & BICC: From "Tech On-Chain" to "Global Redeemability"--RWA Ecosystem Takes Off for Long-Term Growth
- Shineco Unveils World's First On-Chain Cell Asset Tokenization Platform; Strategic Acquisition Expands Global Blockchain-Biotech Network
- Shineco Establishes Biological Cell Digital Division to Integrate Biological Cell Assets and Blockchain Technology
- Shineco, Inc. to Effect 50:1 Reverse Stock Split
- Shineco Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events
- SEC Form DEF 14C filed by Shineco Inc.